in 1981 were estimated to be taking ji blockers,' but nearly all of them would have to have survived because of fl blockade for this to account solely for the increased survival rates; this is unlikely given the modest effect on survival of j i blockers taken after infarction. 12
The hazards of continued smoking after myocardial infarction became widely recognised in the early 1970s,' and as the need to stop smoking now receives much more emphasis in hospital than it did in the 1960s we suspect that this may be the most important factor contributing to improved survival.
Our results suggest that an improvement in long term survival after myocardial infarction contributed to the decline in mortality from coronary heart disease in New Zealand, but there is as yet no evidence that it is continuing to do so. Further reductions in mortality from coronary heart disease are likely only if emphasis is placed on primary prevention.
Abstract
Study objective-To determine whether postmenopausal oestrogen use affects the risk of dying from stroke.
Design-Postal questionnaire survey to elicit details of oestrogen replacement therapy and potential risk modifiers.
Setting-Californian retirement community. Participants-All 22 781 residents of community (white, affluent, weli educated) contacted by mail and phone; 13 986 (61%, median age 73) responded, including 8882 women. These formed cohort for mortality foliow up, using health department death certification. Only 13 lost to follow up, apparently not deceased, but 34 excluded because no information on oestrogen use.
Interventions-None. End point-Mortality rate from stroke compared in women who did and did not receive oestrogen replacement treatment.
Measurements and main results-Age adjusted mortality rates were computed using internal standard and four age groups. By January 1987 there had been 1019 deaths in the cohort. Twenty out of 4962 women who used oestrogen replacement treatment died from stroke compared with 43 out of 3845 women who did not use oestrogen replacement treatment: relative risk 0 53, 95% confidence interval 0*31 to 0*91. Protection was found in all age groups except the youngest and was unaffected by adjustment for possible confounding factors (hypertension, smoking, alcohol, body mass index, exercise).
Introduction
Although mortality rates are declining, stroke continues to be the third leading cause of death in the United States after heart disease and cancer' as well as a major contributor to disability. Since stroke is often fatal and the impact of treatment on prognosis is limited, control of the disease must be through primary prevention.
Recent cohort and case-control studies have suggested that the use of oestrogen replacement treatment by postmenopausal women protects against death and admission to hospital due to cardiovascular disease.2'-" As some of the major risk factors for heart disease are also risk factors for stroke, we examined the association of postmenopausal hormone use and stroke in a prospective study conducted in a retirement community in southern California. The study design provided the opportunity of obtaining details on potential risk modifiers, such as prior heart disease, hypertension, cigarette smoking, alcohol intake, exercise, and weight, as well as on the dose and duration ofuse ofoestrogens.
Methods
In June 1981 a health questionnaire was mailed to all residents of Leisure World, Laguna Hills, a retirement community near Los Angeles, California. New residents who moved into the community after this date were mailed the questionnaire in June 1982, June 1983, and October 1985. Residents of this community are almost entirely white, moderately affluent, and well educated. The residents' median age was 73 at the time of the initial mailing, and about two thirds were women. After three mailings and follow up telephone contact 13 986 (61%) of the 22 781 residents returned questionnaires; 8882 ofthese respondents were women.
The health questionnaire requested information on certain medical diagnoses including stroke, angina, myocardial infarction, and hypertension; height and weight; consumption ofcigarettes and alcohol; and, for women, menstrual and reproductive events, including gynaecological operations. Detailed information was collected on the use of oestrogens during the meno-pause, including routes of administration (injectable, oral, vaginal) and the duration of treatment. For the most commonly used oral oestrogen, Premarin (conjugated oestrogens), the colour of the pills was used to help identify the dosage taken.
'I'he cohort is being followed for deaths using the death certificate records of the local county health department. Death certificates are also obtained for others known to have died because of information from the community business office, from the obituary columns of the local newspaper, and from relatives and friends. We have also conducted a biennial remailing to the cohort. l'o date only 13 cohort members have been lost to follow up; a search of the national death index did not show that they had died.
Age adjusted mortality rates were computed by direct standardisation using an internal standardthat is, the person years distribution of the total cohort under study-6-and four age groups. Relative risks and p values were obtained using a regression method that assumed that the occurrence of death could be regarded as a Poison process with a constant hazard rate for a given person.' The GLIM statistical software package program was used to make these calculations. All reported p values are two-sided.
Results
By 1 January 1987, 1019 deaths had occurred among the 8841 women who returned the initial questionnaire before that date (41 women returned the questionnaire in 1987). Thirty four women provided no intormation on oestrogen use and were excluded from further analyses related to this variable. There were 442 deaths among the 4962 women who had used oestrogen replacement treatment and 563 among the 3845 women who had not, yielding an age-adjusted relative risk (RR) of 0 80 (95% confidence interval 0 70 to 0 91). The age specific and age adjusted death rates for stroke by history of oestrogen use are given in table I. There were 20 deaths due to stroke among the women who had used oestrogen replacement treatment and 43 among those who had never used oestrogens, yielding an age adjusted relative risk of 0(53 (95% confidence interval 0 31 to 0-91). All age groups except the youngest showed a substantial reduction in risk.
A history of stroke (RR=5 2, p<0 0001) and of angina or acute myocardial infarction (RR=2-0), p-=002) were each significant risk factors for death from stroke. Women with a history of hypertension had a non-significantly increased risk of death from stroke (RR= 5, p= 0 12). Current smokers had an increased mortality from stroke compared with those who had never smoked, but this increased risk was not statistically significant. There was a significant trend of decreasing risk with increasing physical exercise (p=0001). In those who had never used oestrogen replacement treatment, the rate of deaths from stroke decreased with increasing body mass index, with increasing age at menopause, and with decreasing alcohol consumption.
Users of oestrogens had a lower mortality from stroke than non-users in the presence or absence of each and all of these potential risk modifiers or confounding variables (table II) . Adjustment for each of these factors separately and simultaneously did not appreciably change the relative risk of mortality from stroke observed for oestrogen users compared with non-users. BMJ VOLUME 297
20-27 AUGUST 1988risk estimates. When duration of use was evaluated by dividing the group into two according to whether the women had taken oestrogen treatment for more or less than the median (8 years) there was no large difference in risk. Protection from death from stroke was greatest among more recent users (p=0O03, test for trend). Recent users (those who were using oestrogen at the time of the initial questionnaires) had a relative risk of 0 21 and past users a risk of 0-67 relative to those who had never had treatment, but the former risk estimate was based on just one death from stroke.
Discussion
These results suggest that postmenopausal oestrogen replacement treatment protects against death due to stroke. Women who had used oestrogen replacement treatment had a risk of mortalitv from stroke of 0-53 relative to women who had never taken menopausal oestrogens. The reduction in risk of death from stroke in oestrogen users was comparable with that previously observed in this community for deaths due to acute mvocardial infarction." This protective effect of oestrogen was not explained by differences between users and non-users in a history of known risk factors for stroke, including previous stroke, angina or myocardial infarction, hypertension, obesity, alcohol consumption, and cigarette smoking.
The only previous study describing the relation between postmenopausal oestrogen treatment and the risk of stroke was done by Pfeffer and Van den Noort,9 who conducted a case-control study covering the period 1964-73 among residents of this same retirement community. Using death certificates and hospital discharge summaries to identify their cases and medical centre pharmacy records to estimate oestrogen exposure, they found no relation between oestrogen use and stroke. By this method of identifying oestrogen exposure, however, only 27% of study subjects had used oestrogen and only 45% of these had used oestrogen for more than 12 months. We have previously expressed concerns about the completeness of these pharmacy records and the potential bias introduced by using records from the convenient pharmacy in the medical centre of the community as the sole source of data on oestrogen use."' As with cardiovascular disease, one possible mechanism for the protection from stroke afforded by oestrogen use is the effect of oestrogens on lipid secretion and metabolism. Users of oestrogen replacement treatment have reduced low density and increased high density lipoprotein cholesterol concentrations. " Although several studies have found no association between lipid concentrations and stroke," ' or a negative association,2 2s, increased serum cholesterol concentrations have been reported as a risk factor in the Framingham study.2" None the less, alternative mechanisms to explain this considerable reduction in the risk of fatal stroke among oestrogen users should be evaluated. For example, oestrogens may cause vasodilatation through their stimulatory effects on prostacyclins.
The major risk factors for stroke have recently been reviewed.)" The results of virtually all the large prospective studies suggest that raised blood pressure is the dominant risk factor."-", l Hypertension was a risk factor in our study population as well. There is a common belief that oestrogen treatment predisposes women to an increase in blood pressure and that hypertension may be a contraindication to oestrogen treatment. ' Importantly, our study showed a reduction in mortality from stroke with oestrogen use in both women with a history of hypertension and those without. Although a small percentage of oestrogen users may experience an idiosyncratic increase in blood pressure, recent studies have shown that most women taking oestrogen replacement treatment actually experience a decline in blood pressure.' "8 We are uncertain whether or not this effect of oestrogen played any part in the reduction of mortality from stroke experienced by oestrogen users in our cohort.
Previous cardiac disease has been identified as a risk factor for stroke by most,, 4' 40 but not allV studies. Our data support the former group of studies.
Results have been less conclusive about the roles of cigarette smoking, alcohol consumption, and obesity. Smoking has been shown to be a risk factor for stroke in men in some studies`43 " but not in others24 and not in women.4 4 Our data suggest an increased risk of death from stroke in past women smokers and those currently smoking relative to those who had never smoked, but this increase was not statistically significant.
Although associated with both hypertension and cigarette smoking, alcohol intake has been found to be independently associated with stroke.6I Recent reports have implicated habitual daily drinking and have shown an excess of deaths from stroke with frequent intoxication or binge drinking.444" Our data suggest some increased risk in the most extreme category of alcohol intake, but only among nonoestrogen users.
Obesity, although related to hypertension, has not been consistently found to be an independent risk factor for stroke. Case I-A 30 year old man received a kidney from his sister. Hyperimmune gammaglobulin was given in a dose of 3 ml immediately before the operation and another dose three months later. Good graft function was achieved. Fifty months after transplantation cyclosporin was substituted for azathioprine because of a slow but steady decline in renal function. The patient remained negative for hepatitis B surface antigen three years after transplantation. Antibodies to hepatitis B surface antigen were detected at two years but persisted for only six months. At the last review the patient's serum creatinine concentration was 276 Fmol/l, and his transaminase activities were normal.
Case 2-A 36 year old man received a kidney from his mother. Before operation and immediately afterwards he was given 4 ml of hyperimmune gammaglobulin. Another dose was given three months later. Good graft function was achieved. The patient developed antibodies to hepatitis B surface antigen at
